ERILs Und SNILs Unter SOC

Stroke, Acute Clinical Trial

Official title: Early Recurrent Ischemic Lesions (ERILs) and Silent Neurologic Ischemic Lesions (SNILs) in Diffusion-weighted Magnetic Resonance Imaging (DW-MRI) - a Pilot- Observational Study Under Standard of Care (SOC)

Status Withdrawn

Clinical Trial Summary

1. How many ERILs occur in caucasian patients with LAA stroke during 7 days on standard treatment? 2. How many SNILs occur between 7 and 30 days after acute ischemic event on standard treatment? 3. How many of during acute event diagnosed lesions (ERILs) are (still) detectable after 30 days? 4. Are there relevant risk faktors for the occurence of ERILs and SNILs (eg Diabetes or Biomarkers)?

Clinical Trial Description

In this trial, patients will be observed if they develop early recurrent ischemic lesions (= ERILs) or silent neurologic ischemic lesions (= SNILs) after acute stroke or transitoric ischemic attack (TIA) based on atherothrombosis (LAA-stroke) on standard therapy during 30 days (day 7 and day 30 after acute event) via DW-MRI (diffusion-weighted magnetic resonance imaging). We want to investigate if diffusion-weighted imaging of silent brain infarcts occuring during standard therapy is a suitable surrogate outcome measure for interventional studies ;

Related Conditions & MeSH terms

• Stroke
• Stroke, Acute

• NCT number: NCT05786170
• Study type: Interventional
• Source: Medical University of Vienna
• Status: Withdrawn
• Phase: N/A
• Start date: September 2019
• Completion date: July 5, 2021